Biotechs’ Size A Competitive Advantage Over Big Pharma In Compliance Arena – BIO Panel
This article was originally published in The Pink Sheet Daily
Smaller biotechs should view current regulatory environment as a way to leverage size to better compete with larger companies, Cubist exec says.
You may also be interested in...
Corporate integrity agreement will be carefully studied in pharmaceutical industry given uncertainties surrounding off-label promotion rules. Pfizer agrees to establish clear policies and keep close tabs on off-label use – but the agreement does not define prohibited or permitted activities.
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.